AdvanCell strengthens cancer drug pipeline with $112m Series C funding

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapy, has successfully completed an oversubscribed $112 million Series C funding round. The investment, co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, marks a significant milestone in the company’s growth and expansion strategy. Additional backing came from existing investor Morningside, as well as new investors Tenmile and Brandon Capital.

The funds will be used to scale AdvanCell’s manufacturing operations, accelerate the clinical development of its targeted radionuclide therapies, and expand its pipeline of cancer treatments. With growing demand for innovative cancer solutions, this financing positions AdvanCell as a leader in the field, particularly in the development of Pb-212-based therapies, which offer a promising new approach to treating aggressive cancers such as metastatic prostate cancer.

What makes AdvanCell’s targeted alpha therapy unique?

AdvanCell is at the forefront of targeted alpha-emitting radionuclide therapies, a highly advanced approach that delivers precise radiation to cancer cells while minimizing damage to healthy tissue. Unlike traditional radiation therapies, which can affect both cancerous and non-cancerous cells, targeted alpha therapy provides a more selective treatment by using alpha-emitting isotopes. The company’s proprietary Pb-212-based therapy capitalizes on the unique properties of lead-212, a powerful isotope with significant potential in precision oncology.

The key advantage of targeted alpha therapy lies in its ability to deliver high-energy radiation over a short range, allowing for greater specificity in eliminating cancer cells. This approach has shown considerable promise in treating metastatic prostate cancer, an area where existing therapies often fall short. AdvanCell’s expertise in scalable radionuclide supply also differentiates it from competitors, as securing a reliable source of Pb-212 has historically been a major challenge in the field. To address this, the company has built a state-of-the-art 40,000-square-foot manufacturing facility, ensuring consistent production capacity to support the growing demand for targeted radionuclide therapies.

How will the new funding accelerate AdvanCell’s clinical pipeline?

With this latest investment, AdvanCell is well-positioned to advance its clinical research and bring its therapies closer to regulatory approval and commercialization. The company’s lead candidate, ADVC001, is currently being evaluated in a Phase I/II TheraPb dose-escalation clinical trial. This study is enrolling patients in the highest-dose cohort, focusing on assessing the safety and efficacy of Pb-212-based targeted alpha therapy in treating metastatic prostate cancer.

Beyond its lead program, AdvanCell continues to expand its research pipeline, exploring additional applications for its targeted radionuclide therapies. The funding will allow the company to accelerate clinical trials, strengthen its preclinical infrastructure, and drive further innovation in the field. With increasing interest in targeted radionuclide therapies, AdvanCell’s platform has the potential to transform treatment approaches for a range of hard-to-treat cancers.

What role do investors and industry leaders play in AdvanCell’s growth?

As part of the financing round, AdvanCell has strengthened its leadership by welcoming new board members with extensive industry expertise. Jamil M. Beg of SV Health Investors, Christopher Gagliardi of Sanofi Ventures, and Bali Muralidhar of Abingworth have joined the AdvanCell Board of Directors, bringing deep experience in biopharmaceutical investments and clinical-stage company growth. Their insights and strategic guidance will be instrumental in steering the company through its next phase of development.

Jamil M. Beg emphasized AdvanCell’s strong position in the radiopharmaceutical sector, noting that the company’s Pb-212-PSMA program and its advanced manufacturing capabilities set it apart. He highlighted AdvanCell’s ability to integrate cutting-edge science with scalable production, a factor that has been critical in securing investor confidence. With established collaborations with leading pharmaceutical companies, AdvanCell is well-positioned to drive significant advancements in the field of targeted radionuclide therapy.

What does this funding mean for the future of radionuclide cancer treatments?

AdvanCell was founded on the belief that targeted alpha therapy could revolutionize cancer treatment, particularly for patients with limited therapeutic options. The success of this Series C funding round reflects growing investor confidence in next-generation radionuclide therapies and their potential to improve patient outcomes.

With increased resources, AdvanCell is set to expand its manufacturing capacity, ensuring a steady supply of Pb-212 for its clinical programs. The company will also focus on advancing its lead candidates through the regulatory approval process while exploring new applications for its proprietary technology. By bridging the gap between research and patient care, AdvanCell aims to bring life-changing treatments to individuals battling aggressive cancers.

What’s next for AdvanCell?

With strong financial backing and a clear strategic direction, AdvanCell is poised for rapid growth in the radiopharmaceutical space. The company’s ongoing clinical trials, robust preclinical infrastructure, and commitment to innovation make it a key player in shaping the future of precision oncology. As it moves closer to commercialization, AdvanCell’s targeted alpha therapies could redefine the standard of care for prostate cancer and other challenging malignancies.

By focusing on scalable, high-impact treatments, the company continues to drive advancements in radionuclide therapy development. With the support of its investors and strategic partners, AdvanCell is set to play a crucial role in transforming oncology treatment on a global scale.